News & Videos - OREXO AB [CBOE]

Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US PR Newswire UPPSALA, Sweden, April 17, 2024 UPPSALA, Sweden , April 17, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces that the United States Patent and Trademark Office (USPTO) has granted another US patent specifically related to OX640, Orexo's nasal epinephrine powder product based on the AmorphOX® drug delivery platform. In August 2023 , the USPTO granted the first...

Orexo announces that the condition for early redemption of its existing bonds has been fulfilled PR Newswire UPPSALA, Sweden, April 2, 2024 UPPSALA, Sweden, April 2, 2024 /PRNewswire/ -- On March 13 , 2024, Orexo AB (publ), (" Orexo " or the " Company ") (STO:ORX) (OTCQX:ORXOY) announced that the Company intends to redeem early the Company's existing senior unsecured bonds with maturity in February 2025 (ISIN SE0015193958) (the " Existing Bonds "). The early redemption was conditional upon that...

Orexo announces that the condition for early redemption of its existing bonds has been fulfilled PR Newswire UPPSALA, Sweden, April 2, 2024 UPPSALA, Sweden , April 2, 2024 /PRNewswire/ -- On March 13 , 2024, Orexo AB (publ), (" Orexo " or the " Company ") (STO:ORX) (OTCQX:ORXOY) announced that the Company intends to redeem early the Company's existing senior unsecured bonds with maturity in February 2025 (ISIN SE0015193958) (the " Existing Bonds "). The early redemption was conditional upon that...

Orexo publishes the Annual and Sustainability Report for 2023 PR Newswire UPPSALA, Sweden, March 28, 2024 UPPSALA, Sweden , March 28, 2024 /PRNewswire/ -- Orexo's Annual and Sustainability Report for 2023 has been published and can be downloaded at, www.orexo.com . The Swedish version of the Report is also available on the company's website in European Single Electronic Format (ESEF). A PDF version is attached to this press release. Nikolaj Sørensen, President and CEO, said: "In 2023, we...

Orexo publishes the Annual and Sustainability Report for 2023 PR Newswire UPPSALA, Sweden, March 28, 2024 UPPSALA, Sweden , March 28, 2024 /PRNewswire/ -- Orexo's Annual and Sustainability Report for 2023 has been published and can be downloaded at, www.orexo.com . The Swedish version of the Report is also available on the company's website in European Single Electronic Format (ESEF). A PDF version is attached to this press release. Nikolaj Sørensen, President and CEO, said: "In 2023, we...

Correction: Notice of Annual General Meeting of Orexo PR Newswire UPPSALA, Sweden, March 22, 2024 The correction concerns the proposal regarding the number of board members as stated in the Swedish language version of the notice, which shall be five with no deputy members. UPPSALA, Sweden, March 22, 2024 /PRNewswire/ -- The shareholders in Orexo AB (publ), reg. no. 556500-0600, registered office Uppsala, are summoned to the annual general meeting, to be held on Friday 26 April 2024 , at 16.00 pm...

Correction: Notice of Annual General Meeting of Orexo PR Newswire UPPSALA, Sweden, March 22, 2024 The correction concerns the proposal regarding the number of board members as stated in the Swedish language version of the notice, which shall be five with no deputy members. UPPSALA, Sweden , March 22, 2024 /PRNewswire/ -- The shareholders in Orexo AB (publ), reg. no. 556500-0600, registered office Uppsala, are summoned to the annual general meeting, to be held on Friday 26 April 2024 , at 16.00...

Notice of Annual General Meeting of Orexo PR Newswire UPPSALA, Sweden, March 15, 2024 UPPSALA, Sweden , March 15, 2024 /PRNewswire/ -- The shareholders in Orexo AB (publ), reg. no. 556500-0600, registered office Uppsala, are summoned to the annual general meeting, to be held on Friday 26 April 2024 , at 16.00 pm in Orexo's facilities at Rapsgatan 7E in Uppsala, Sweden . Participation, etc. Shareholders who wish to participate in the meeting must be recorded in the share register maintained by...

Orexo successfully issues senior secured callable floating rate social bonds of SEK 500 m and announces results of the tender offer for its existing bonds PR Newswire UPPSALA, Sweden, March 13, 2024 UPPSALA, Sweden , March 13, 2024 /PRNewswire/ -- Orexo AB (publ), (" Orexo " or the " Company ") (STO:ORX) (OTCQX:ORXOY) has successfully issued new senior secured callable floating rate social bonds in an amount of SEK 500 million and with a tenor of four years (the " New Social Bonds "). The New...

Orexo successfully issues senior secured callable floating rate social bonds of SEK 500 m and announces results of the tender offer for its existing bonds PR Newswire UPPSALA, Sweden, March 13, 2024 UPPSALA, Sweden , March 13, 2024 /PRNewswire/ -- Orexo AB (publ), (" Orexo " or the " Company ") (STO:ORX) (OTCQX:ORXOY) has successfully issued new senior secured callable floating rate social bonds in an amount of SEK 500 million and with a tenor of four years (the " New Social Bonds "). The New...

Orexo strengthens its sustainability work by establishing a social financing framework PR Newswire UPPSALA, Sweden, March 8, 2024 UPPSALA, Sweden , March 8, 2024 /PRNewswire/ -- Orexo AB (publ), ('Orexo' or the 'Company') (STO: ORX) (OTCQX: ORXOY) today announces that the Company has established a social financing framework dated February 2024 (the 'Social Framework'), which enables Orexo to issue social bonds and potentially raise social loans, as well as other type of debt instruments...

Orexo contemplates issuance of senior secured callable floating rate social bonds and announces a conditional tender offer for its existing bonds PR Newswire UPPSALA, Sweden, March 8, 2024 UPPSALA, Sweden , March 8, 2024 /PRNewswire/ -- Orexo AB (publ), (" Orexo " or the " Company ") (STO: ORX) (OTCQX: ORXOY) has mandated ABG Sundal Collier and Carnegie Investment Bank as arrangers and joint bookrunners to arrange a series of fixed income investor meetings commencing on March 11, 2024 , to...

Orexo strengthens its sustainability work by establishing a social financing framework PR Newswire UPPSALA, Sweden, March 8, 2024 UPPSALA, Sweden , March 8, 2024 /PRNewswire/ -- Orexo AB (publ), ('Orexo' or the 'Company') (STO: ORX) (OTCQX: ORXOY) today announces that the Company has established a social financing framework dated February 2024 (the 'Social Framework'), which enables Orexo to issue social bonds and potentially raise social loans, as well as other type of debt instruments...

Orexo contemplates issuance of senior secured callable floating rate social bonds and announces a conditional tender offer for its existing bonds PR Newswire UPPSALA, Sweden, March 8, 2024 UPPSALA, Sweden , March 8, 2024 /PRNewswire/ -- Orexo AB (publ), (" Orexo " or the " Company ") (STO: ORX) (OTCQX: ORXOY) has mandated ABG Sundal Collier and Carnegie Investment Bank as arrangers and joint bookrunners to arrange a series of fixed income investor meetings commencing on March 11, 2024 , to...

Orexo and Sobi agree to advance feasibility study with AmorphOX PR Newswire UPPSALA, Sweden, Feb. 12, 2024 Orexo and Sobi advance collaboration after successful exploratory feasibility study with the company´s world-class drug delivery platform, AmorphOX® The feasibility study confirmed that the biomolecule retained its activity after formulation with AmorphOX Orexo has patent applications for AmorphOX formulations relating to biomolecules. UPPSALA, Sweden , Feb. 12, 2024 /PRNewswire/ -- Orexo...

Orexo Interim Report Q4 2023, incl. Full Year Report PR Newswire UPPSALA, Sweden, Feb. 8, 2024 UPPSALA, Sweden , Feb. 8, 2024 /PRNewswire/ -- Positive EBITDA in H2 setting the target for FY 2024 Q4 2023 highlights Total net revenues of SEK 166.0 m (156.1) EBITDA of SEK 12.4 m (-53.1), EBITDA excluding costs for legal processes and external non-­repeating ­­clinical trials, SEK 23.4 m (-0.1) Net earnings of SEK -18.6 m (-91.8) US Pharma segment (Zubsolv ® US) net revenues of SEK 151.3 m...

Orexo Interim Report Q4 2023, incl. Full Year Report PR Newswire UPPSALA, Sweden, Feb. 8, 2024 UPPSALA, Sweden , Feb. 8, 2024 /PRNewswire/ -- Positive EBITDA in H2 setting the target for FY 2024 Q4 2023 highlights Total net revenues of SEK 166.0 m (156.1) EBITDA of SEK 12.4 m (-53.1), EBITDA excluding costs for legal processes and external non-­repeating ­­clinical trials, SEK 23.4 m (-0.1) Net earnings of SEK -18.6 m (-91.8) US Pharma segment (Zubsolv ® US) net revenues of SEK 151.3 m...

Orexo's OX640 development results to be presented at the 2024 AAAAI Annual Meeting in Washington, DC PR Newswire UPPSALA, Sweden, Feb. 6, 2024 OX640 is Orexo's nasal epinephrine powder product for the acute treatment of severe allergic reactions including anaphylaxis, based on the company´s proprietary drug delivery platform, AmorphOX® The American Academy of Allergy, Asthma & Immunology (AAAAI) is the largest professional medical organization in the United States devoted to the...

Orexo announces FDA acceptance of New Drug Application filing for OX124, a high-dose rescue medication for opioid overdose PR Newswire UPPSALA, Sweden, Nov. 28, 2023 OX124 is based on Orexo´s world-class drug delivery platform, amorphOX®, and is designed to reverse the effects of the most powerful synthetic opioids, such as fentanyl Synthetic opioids are behind 91 percent of all fatal opioid overdoses in the US [1 ] Prescription Drug User Fee Act date (PDUFA) set to July 15, 2024 . If...

Orexo Q3 2023 Interim Report PR Newswire UPPSALA, Sweden, Nov. 2, 2023 Big step forward in launching OX124 in the US UPPSALA, Sweden , Nov. 2, 2023 /PRNewswire/ -- Q3 2023 highlights › Total net revenues of SEK 156.1 m (161.0) › EBITDA of SEK -9.5 m (-32.4), EBITDA excluding costs for legal processes and external non-­repeating ­­clinical trials, SEK 13.3 m (14.3) › Net earnings of SEK -33.3 m (-26.5) › US Pharma segment (ZUBSOLV® US) net revenues of SEK 140.4 m (150.1), in local...